Search

Your search keyword '"de Ferranti, Sarah"' showing total 864 results
Start Over Author "de Ferranti, Sarah" Publication Year Range Last 50 years
864 results on '"de Ferranti, Sarah"'

2. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Author

Watts, Gerald F., Gidding, Samuel S., Hegele, Robert A., Raal, Frederick J., Sturm, Amy C., Jones, Laney K., Sarkies, Mitchell N., Al-Rasadi, Khalid, Blom, Dirk J., Daccord, Magdalena, de Ferranti, Sarah D., Folco, Emanuela, Libby, Peter, Mata, Pedro, Nawawi, Hapizah M., Ramaswami, Uma, Ray, Kausik K., Stefanutti, Claudia, Yamashita, Shizuya, Pang, Jing, Thompson, Gilbert R., and Santos, Raul D.

Published
2023
Full Text
View/download PDF

5. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN

Author

Reijman, M. Doortje, Kusters, D. Meeike, Groothoff, Jaap W., Arbeiter, Klaus, Dann, Eldad J., de Boer, Lotte M., de Ferranti, Sarah D., Gallo, Antonio, Greber-Platzer, Susanne, Hartz, Jacob, Hudgins, Lisa C., Ibarretxe, Daiana, Kayikcioglu, Meral, Klingel, Reinhard, Kolovou, Genovefa D., Oh, Jun, Planken, R. Nils, Stefanutti, Claudia, Taylan, Christina, Wiegman, Albert, and Schmitt, Claus Peter

Published
2024
Full Text
View/download PDF

9. Evidence-Based Policy Making for Public Health Interventions in Cardiovascular Diseases: Formally Assessing the Feasibility of Clinical Trials

Author

Foti, Kathryn, Foraker, Randi E, Martyn-Nemeth, Pamela, Anderson, Cheryl AM, Cook, Nancy R, Lichtenstein, Alice H, de Ferranti, Sarah D, Young, Deborah Rohm, Hivert, Marie-France, Ross, Robert, Deedwania, Prakash, Whitsel, Laurie P, and Appel, Lawrence J

Subjects
Comparative Effectiveness Research, Clinical Trials and Supportive Activities, Clinical Research, Cardiovascular, Prevention, 8.4 Research design and methodologies (health services), Health and social care services research, 8.3 Policy, ethics, and research governance, Generic health relevance, Good Health and Well Being, Cardiovascular Diseases, Diet, Sodium-Restricted, Evidence-Based Medicine, Feasibility Studies, Humans, Policy Making, Preventive Health Services, Public Health, Randomized Controlled Trials as Topic, Research Design, Risk Reduction Behavior, Treatment Outcome, cardiovascular disease, decision-making, policy, prevention, public health, randomized controlled trial, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

Implementation of prevention policies has often been impeded or delayed due to the lack of randomized controlled trials (RCTs) with hard clinical outcomes (eg, incident disease, mortality). Despite the prominent role of RCTs in health care, it may not always be feasible to conduct RCTs of public health interventions with hard outcomes due to logistical and ethical considerations. RCTs may also lack external validity and have limited generalizability. Currently, there is insufficient guidance for policymakers charged with establishing evidence-based policy to determine whether an RCT with hard outcomes is needed before policy recommendations. In this context, the purpose of this article is to assess, in a case study, the feasibility of conducting an RCT of the oft-cited issue of sodium reduction on cardiovascular outcomes and then propose a framework for decision-making, which includes an assessment of the feasibility of conducting an RCT with hard clinical outcomes when such trials are unavailable. We designed and assessed the feasibility of potential individual- and cluster-randomized trials of sodium reduction on cardiovascular outcomes. Based on our assumptions, a trial using any of the designs considered would require tens of thousands of participants and cost hundreds of millions of dollars, which is prohibitively expensive. Our estimates may be conservative given several key challenges, such as the unknown costs of sustaining a long-term difference in sodium intake, the effect of differential cotreatment with antihypertensive medications, and long lag time to clinical outcomes. Thus, it would be extraordinarily difficult to conduct such a trial, and despite the high costs, would still be at substantial risk for a spuriously null result. A robust framework, such as the one we developed, should be used to guide policymakers when establishing evidence-based public health interventions in the absence of trials with hard clinical outcomes.

Published
2020

12. Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry.

Author

McCrindle, Brian W, Manlhiot, Cedric, Newburger, Jane W, Harahsheh, Ashraf S, Giglia, Therese M, Dallaire, Frederic, Friedman, Kevin, Low, Tisiana, Runeckles, Kyle, Mathew, Mathew, Mackie, Andrew S, Choueiter, Nadine F, Jone, Pei-Ni, Kutty, Shelby, Yetman, Anji T, Raghuveer, Geetha, Pahl, Elfriede, Norozi, Kambiz, McHugh, Kimberly E, Li, Jennifer S, De Ferranti, Sarah D, Dahdah, Nagib, and International Kawasaki Disease Registry *

Subjects
International Kawasaki Disease Registry *, Coronary Vessels, Humans, Coronary Aneurysm, Mucocutaneous Lymph Node Syndrome, Registries, Risk Assessment, Retrospective Studies, Child, Child, Preschool, Infant, Female, Male, Kawasaki disease, cardiovascular outcomes, coronary artery, risk factors, Prevention, Cardiovascular, Heart Disease - Coronary Heart Disease, Heart Disease, Cardiorespiratory Medicine and Haematology
Abstract

Background Coronary artery aneurysms (CAAs) may occur after Kawasaki disease (KD) and lead to important morbidity and mortality. As CAA in patients with KD are rare and heterogeneous lesions, prognostication and risk stratification are difficult. We sought to derive the cumulative risk and associated factors for cardiovascular complications in patients with CAAs after KD. Methods and Results A 34-institution international registry of 1651 patients with KD who had CAAs (maximum CAA Z score ≥2.5) was used. Time-to-event analyses were performed using the Kaplan-Meier method and Cox proportional hazard models for risk factor analysis. In patients with CAA Z scores ≥10, the cumulative incidence of luminal narrowing (>50% of lumen diameter), coronary artery thrombosis, and composite major adverse cardiovascular complications at 10 years was 20±3%, 18±2%, and 14±2%, respectively. No complications were observed in patients with a CAA Z score

Published
2020

18. Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events

Author

Zhang, Yiyi, Vittinghoff, Eric, Pletcher, Mark J, Allen, Norrina B, Hazzouri, Adina Zeki Al, Yaffe, Kristine, Balte, Pallavi P, Alonso, Alvaro, Newman, Anne B, Ives, Diane G, Rana, Jamal S, Lloyd-Jones, Donald, Vasan, Ramachandran S, Bibbins-Domingo, Kirsten, Gooding, Holly C, de Ferranti, Sarah D, Oelsner, Elizabeth C, and Moran, Andrew E

Subjects
Aging, Prevention, Clinical Research, Cardiovascular, Heart Disease, Good Health and Well Being, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Blood Pressure, Cardiovascular Diseases, Child, Child, Preschool, Cholesterol, HDL, Cholesterol, LDL, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Young Adult, blood pressure, cholesterol, coronary heart disease, heart failure, stroke, young adulthood, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

BackgroundBlood pressure (BP) and cholesterol are major modifiable risk factors for cardiovascular disease (CVD), but effects of exposures during young adulthood on later life CVD risk have not been well quantified.ObjectiveThe authors sought to evaluate the independent associations between young adult exposures to risk factors and later life CVD risk, accounting for later life exposures.MethodsThe authors pooled data from 6 U.S. cohorts with observations spanning the life course from young adulthood to later life, and imputed risk factor trajectories for low-density lipoprotein (LDL) and high-density lipoprotein cholesterols, systolic and diastolic BP starting from age 18 years for every participant. Time-weighted average exposures to each risk factor during young (age 18 to 39 years) and later adulthood (age ≥40 years) were calculated and linked to subsequent risks of coronary heart disease (CHD), heart failure (HF), or stroke.ResultsA total of 36,030 participants were included. During a median follow-up of 17 years, there were 4,570 CHD, 5,119 HF, and 2,862 stroke events. When young and later adult risk factors were considered jointly in the model, young adult LDL ≥100 mg/dl (compared with

Published
2019

19. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population

Author

Son, Mary Beth F, Gauvreau, Kimberlee, Tremoulet, Adriana H, Lo, Mindy, Baker, Annette L, de Ferranti, Sarah, Dedeoglu, Fatma, Sundel, Robert P, Friedman, Kevin G, Burns, Jane C, and Newburger, Jane W

Subjects
Heart Disease, Cardiovascular, Prevention, Heart Disease - Coronary Heart Disease, Clinical Research, Adolescent, Age Factors, Asian Americans, Biomarkers, Boston, C-Reactive Protein, California, Child, Child, Preschool, Coronary Aneurysm, Disease Progression, Echocardiography, Female, Humans, Infant, Male, Mucocutaneous Lymph Node Syndrome, Predictive Value of Tests, Prospective Studies, Randomized Controlled Trials as Topic, Reproducibility of Results, Retrospective Studies, Risk Assessment, Risk Factors, coronary aneurysm, echocardiography, Kawasaki disease, risk score, Asian, Cardiorespiratory Medicine and Haematology
Abstract

Background Accurate prediction of coronary artery aneurysms ( CAAs ) in patients with Kawasaki disease remains challenging in North American cohorts. We sought to develop and validate a risk model for CAA prediction. Methods and Results A binary outcome of CAA was defined as left anterior descending or right coronary artery Z score ≥2.5 at 2 to 8 weeks after fever onset in a development cohort (n=903) and a validation cohort (n=185) of patients with Kawasaki disease. Associations of baseline clinical, laboratory, and echocardiographic variables with later CAA were assessed in the development cohort using logistic regression. Discrimination (c statistic) and calibration (Hosmer-Lemeshow) of the final model were evaluated. A practical risk score assigning points to each variable in the final model was created based on model coefficients from the development cohort. Predictors of CAAs at 2 to 8 weeks were baseline Z score of left anterior descending or right coronary artery ≥2.0, age 40-fold greater in the validation cohort (odds ratio, 44.0; 95% CI, 10.8-180 [ P

Published
2019

20. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.

Author

Dionne, Audrey, Burns, Jane C, Dahdah, Nagib, Tremoulet, Adriana H, Gauvreau, Kimberlee, de Ferranti, Sarah D, Baker, Annette L, Son, Mary Beth, Gould, Patrick, Fournier, Anne, Newburger, Jane W, and Friedman, Kevin G

Subjects
Humans, Coronary Aneurysm, Mucocutaneous Lymph Node Syndrome, Immunoglobulins, Intravenous, Antirheumatic Agents, Treatment Outcome, Risk Factors, Retrospective Studies, Follow-Up Studies, Adolescent, Child, Child, Preschool, Infant, Female, Male, Infliximab, Immunoglobulins, Intravenous, Preschool, Medical and Health Sciences, Psychology and Cognitive Sciences, Pediatrics
Abstract

BackgroundCoronary artery aneurysms (CAA) are a serious complication of Kawasaki disease. Treatment with intravenous immunoglobulin (IVIg) within 10 days of fever onset reduces the risk of CAA from 25% to

Published
2019

21. Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease.

Author

de Ferranti, Sarah D, Gauvreau, Kimberlee, Friedman, Kevin G, Tang, Alexander, Baker, Annette L, Fulton, David R, Tremoulet, Adriana H, Burns, Jane C, and Newburger, Jane W

Subjects
Coronary Vessels, Humans, Mucocutaneous Lymph Node Syndrome, Echocardiography, Retrospective Studies, Follow-Up Studies, Child, Preschool, Infant, Female, Male, Coronary Artery Disease, Child, Preschool, Pediatrics, Paediatrics and Reproductive Medicine
Abstract

ImportanceAmerican Heart Association guidelines recommend echocardiography in Kawasaki disease at baseline, 1 to 2 weeks, and 4 to 6 weeks after treatment to detect coronary artery abnormalities. However, these examinations are expensive and may require sedation in young children, which is burdensome and carries some risk.ObjectiveTo assess the benefit of additional echocardiographic imaging at 6 weeks in patients with uncomplicated Kawasaki disease who had previously normal coronary arteries.Design, setting, and participantsThis is a retrospective review of patients with Kawasaki disease who were cared for between 1995 and 2014 in 2 academic pediatric referral practices Eligibility criteria included receiving intravenous immunoglobulin treatment for acute Kawasaki disease at a center; the absence of significant congenital heart disease; available echocardiographic measurements of both the right and left anterior descending coronary arteries at 10 days or less after diagnosis (baseline), 2 (±1) weeks, and 6 (±3) weeks of illness; and normal coronary arteries at baseline and 2 weeks, defined as maximum coronary artery z scores less than 2.0 and no distal aneurysms. Data analysis was completed from March 2015 to November 2015.Main outcomes and measuresThe number of patients with right coronary artery or left anterior descending coronary artery z scores of 2.0 or more at 6 weeks.ResultsThe median age of the 464 included patients was 3.3 years (interquartile range, 1.8-5.4 years); 264 (56.9%) were male, 351 of 414 for whom data were available (84.8%) had complete Kawasaki disease, and 66 (14.2%) received additional intravenous immunoglobulin treatment. At 6 weeks of illness, 456 patients (98.3%) who had had normal coronary artery z scores at baseline and 2 weeks continued to have normal z scores. Of the remaining 8 patients (1.7%), the maximum z score within 6 weeks was 2.0 to 2.4 in 5 patients (1.2%), 2.5 to 2.9 in 1 patient (0.2%), and 3.0 or more in 2 patients (0.4% [95% CI, 0.1%-1.5%]). Coronary artery dimensions ultimately normalized in all but 1 patient, who had minimal dilation at 6 weeks (right coronary artery z score, 2.1). Sensitivity analyses using less restrictive cut points (eg, a maximum z score

Published
2018

22. Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease

Author

Zhang, Yiyi, Dron, Jacqueline S., Bellows, Brandon K., Khera, Amit V., Liu, Junxiu, Balte, Pallavi P., Oelsner, Elizabeth C., Amr, Sami Samir, Lebo, Matthew S., Nagy, Anna, Peloso, Gina M., Natarajan, Pradeep, Rotter, Jerome I., Willer, Cristen, Boerwinkle, Eric, Ballantyne, Christie M., Lutsey, Pamela L., Fornage, Myriam, Lloyd-Jones, Donald M., Hou, Lifang, Psaty, Bruce M., Bis, Joshua C., Floyd, James S., Vasan, Ramachandran S., Heard-Costa, Nancy L., Carson, April P., Hall, Michael E., Rich, Stephen S., Guo, Xiuqing, Kazi, Dhruv S., de Ferranti, Sarah D., and Moran, Andrew E.

Published
2023
Full Text
View/download PDF

23. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050--Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association.

Author

Maddox, Karen E. Joynt, Elkind, Mitchell S. V., Aparicio, Hugo J., Commodore-Mensah, Yvonne, de Ferranti, Sarah D., Dowd, William N., Hernandez, Adrian F., Khavjou, Olga, Michos, Erin D., Palaniappan, Latha, Penko, Joanne, Poudel, Remy, Roger, Véronique L., and Kazi, Dhruv S.

Published
2024
Full Text
View/download PDF

25. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol

Author

Zhang, Yiyi, primary, Dron, Jacqueline S., additional, Bellows, Brandon K., additional, Khera, Amit V., additional, Liu, Junxiu, additional, Balte, Pallavi P., additional, Oelsner, Elizabeth C., additional, Amr, Sami Samir, additional, Lebo, Matthew S., additional, Nagy, Anna, additional, Peloso, Gina M., additional, Natarajan, Pradeep, additional, Rotter, Jerome I., additional, Willer, Cristen, additional, Boerwinkle, Eric, additional, Ballantyne, Christie M., additional, Lutsey, Pamela L., additional, Fornage, Myriam, additional, Lloyd-Jones, Donald M., additional, Hou, Lifang, additional, Psaty, Bruce M., additional, Bis, Joshua C., additional, Floyd, James S., additional, Vasan, Ramachandran S., additional, Heard-Costa, Nancy L., additional, Carson, April P., additional, Hall, Michael E., additional, Rich, Stephen S., additional, Guo, Xiuqing, additional, Kazi, Dhruv S., additional, de Ferranti, Sarah D., additional, and Moran, Andrew E., additional

Published
2024
Full Text
View/download PDF

30. Fruit Juice in Infants, Children, and Adolescents: Current Recommendations

Author

Heyman, Melvin B, Abrams, Steven A, Heitlinger, Leo A, Cabana, Michael deCastro, Gilger, Mark A, Gugig, Roberto, Hill, Ivor D, Lightdale, Jenifer R, Daniels, Stephen R, Corkins, Mark R, de Ferranti, Sarah D, Golden, Neville H, Magge, Sheela N, and Schwarzenberg, Sarah J

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Pediatric, Clinical Research, Nutrition, Oral and gastrointestinal, Adolescent, Child, Child Nutritional Physiological Phenomena, Child, Preschool, Diarrhea, Diet, Dietary Carbohydrates, Energy Intake, Fruit and Vegetable Juices, Gastrointestinal Absorption, Humans, Infant, Pediatrics, United States, SECTION ON GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION, COMMITTEE ON NUTRITION, Medical and Health Sciences, Psychology and Cognitive Sciences, Biomedical and clinical sciences, Health sciences, Psychology
Abstract

Historically, fruit juice was recommended by pediatricians as a source of vitamin C and as an extra source of water for healthy infants and young children as their diets expanded to include solid foods with higher renal solute load. It was also sometimes recommended for children with constipation. Fruit juice is marketed as a healthy, natural source of vitamins and, in some instances, calcium. Because juice tastes good, children readily accept it. Although juice consumption has some benefits, it also has potential detrimental effects. High sugar content in juice contributes to increased calorie consumption and the risk of dental caries. In addition, the lack of protein and fiber in juice can predispose to inappropriate weight gain (too much or too little). Pediatricians need to be knowledgeable about juice to inform parents and patients on its appropriate uses.

Published
2017

33. Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial

Author

Altman, Carolyn A., Anderson, Brett R., Braunlin, Elizabeth, Burns, Jane C., Carr, Michael R., Choueiter, Nadine F., Colyer, Jessica H., Crean, Andrew, Dempsey, Adam, Desjardins, Laurent, Dillenburg, Rejane, Dionne, Audrey, Ferris, Anna, Gewitz, Michael, Grcic, Michelle M., Greenway, Steven C., Hamel-Perrault, Elodie, Harris, Kevin C., Hayden-Rush, Christina, Hill, Kevin D., Jain, Supriya, Jone, Pei-Ni, Kimball, Thomas R., Lang, Sean M., Li, Jennifer S., Lin, Ming-Tai, Mahle, William T., McHugh, Kimberly E., Portman, Michael A., Renaud, Claudia, Sexson Tejitel, S. Kristen, Szmuszkovicz, Jacqueline R., Texter, Karen M., Thacker, Deepika, Selamet Tierney, Elif Seda, Thomas, Thomas, Tremoulet, Adriana H., Wagner-Lees, Sharon, Warren, Andrew, Manlhiot, Cedric, Newburger, Jane W., Low, Tisiana, Dahdah, Nagib, Mackie, Andrew S., Raghuveer, Geetha, Giglia, Therese M., Dallaire, Frederic, Mathew, Mathew, Runeckles, Kyle, Pahl, Elfriede, Harahsheh, Ashraf S., Norozi, Kambiz, de Ferranti, Sarah D., Friedman, Kevin, Yetman, Anji T., Kutty, Shelby, Mondal, Tapas, and McCrindle, Brian W.

Published
2020
Full Text
View/download PDF

35. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry

Author

Luirink, Ilse K., Hutten, Barbara A., Greber-Platzer, Susanne, Kolovou, Genovefa D., Dann, Eldad J., de Ferranti, Sarah D., Taylan, Christina, Bruckert, Eric, Saheb, Samir, Oh, Jun, Driemeyer, Joenna, Farnier, Michel, Pape, Lars, Schmitt, Claus P., Novoa, Francisco J., Maeser, Martin, Masana, Luis, Shahrani, Awad, Wiegman, Albert, and Groothoff, Jaap W.

Published
2020
Full Text
View/download PDF

36. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children

Author

Lee, Pui Y., Day-Lewis, Megan, Henderson, Lauren A., Friedman, Kevin G., Lo, Jeffrey, Roberts, Jordan E., Lo, Mindy S., Platt, Craig D., Chou, Janet, Hoyt, Kacie J., Baker, Annette L., Banzon, Tina M., Chang, Margaret H., Cohen, Ezra, de Ferranti, Sarah D., Dionne, Audrey, Habiballah, Saddiq, Halyabar, Olha, Hausmann, Jonathan S., Hazen, Melissa M., Janssen, Erin, Meidan, Esra, Nelson, Ryan W., Nguyen, Alan A., Sundel, Robert P., Dedeoglu, Fatma, Nigrovic, Peter A., Newburger, Jane W., and Son, Mary Beth F.

Subjects
Immunodiagnosis -- Research, Pediatric research, Inflammation -- Diagnosis -- Complications and side effects, COVID-19 -- Diagnosis -- Complications and side effects, Pediatric multisystem inflammatory syndrome -- Diagnosis -- Complications and side effects, Health care industry
Abstract

BACKGROUND. Pediatric SARS-CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C and its relationship to other inflammatory conditions of childhood have not been studied in detail. METHODS. We retrospectively studied confirmed cases of MIS-C at our institution from March to June 2020. The clinical characteristics, laboratory studies, and treatment response were collected. Data were compared with historic cohorts of Kawasaki disease (KD) and macrophage activation syndrome (MAS). RESULTS. Twenty-eight patients fulfilled the case definition of MIS-C. Median age at presentation was 9 years (range: 1 month to 17 years); 50% of patients had preexisting conditions. All patients had laboratory confirmation of SARS- CoV-2 infection. Seventeen patients (61%) required intensive care, including 7 patients (25%) who required inotrope support. Seven patients (25%) met criteria for complete or incomplete KD, and coronary abnormalities were found in 6 cases. Lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common but not ubiquitous. Cytopenias distinguished MIS-C from KD and the degree of hyperferritinemia and pattern of cytokine production differed between MIS-C and MAS. Immunomodulatory therapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). Clinical and laboratory improvement were observed in all cases, including 6 cases that did not require immunomodulatory therapy. No mortality was recorded in this cohort. CONCLUSION. MIS-C encompasses a broad phenotypic spectrum with clinical and laboratory features distinct from KD and MAS. FUNDING. This work was supported by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Allergy and Infectious Diseases; Rheumatology Research Foundation Investigator Awards and Medical Education Award; Boston Children's Hospital Faculty Career Development Awards; the McCance Family Foundation; and the Samara Jan Turkel Center., Introduction Since the onset of the Coronavirus disease 2019 (COVID-19) pandemic, millions of individuals have been infected with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and more than 500,000 deaths [...]

Published
2020
Full Text
View/download PDF

37. Heart Disease and Stroke Statistics—2016 Update

Author

Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, and Turner, Melanie B

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Health Sciences, Clinical Sciences, Sports Science and Exercise, American Heart Association, Data Interpretation, Statistical, Heart Diseases, Humans, Life Style, Research Report, Stroke, United States, AHA Scientific Statements, cardiovascular diseases, epidemiology, risk factors, statistics, stroke, Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences, Sports science and exercise
Published
2016

38. Executive Summary

Author

Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, and Turner, Melanie B

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Health Sciences, Clinical Sciences, Sports Science and Exercise, American Heart Association, Data Interpretation, Statistical, Health Behavior, Heart Diseases, Humans, Research Report, Stroke, United States, AHA Scientific Statements, cardiovascular diseases, epidemiology, risk factors, statistics, stroke, Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences, Sports science and exercise
Published
2016

39. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association.

Author

Writing Group Members, Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, Turner, Melanie B, American Heart Association Statistics Committee, and Stroke Statistics Subcommittee

Subjects
Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee, Humans, Heart Diseases, Data Interpretation, Statistical, Health Behavior, American Heart Association, United States, Stroke, Research Report, AHA Scientific Statements, cardiovascular diseases, epidemiology, risk factors, statistics, stroke, Data Interpretation, Statistical, Clinical Sciences, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Published
2016

40. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.

Author

Writing Group Members, Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, Turner, Melanie B, American Heart Association Statistics Committee, and Stroke Statistics Subcommittee

Subjects
Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee, Humans, Heart Diseases, Data Interpretation, Statistical, Life Style, American Heart Association, United States, Stroke, Research Report, AHA Scientific Statements, cardiovascular diseases, epidemiology, risk factors, statistics, stroke, Data Interpretation, Statistical, Clinical Sciences, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Published
2016

41. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN

Author

Reijman, M. Doortje, primary, Kusters, D. Meeike, additional, Groothoff, Jaap W., additional, Arbeiter, Klaus, additional, Dann, Eldad J., additional, de boer, Lotte M., additional, de Ferranti, Sarah D., additional, Gallo, Antonio, additional, Greber-Platzer, Susanne, additional, Hartz, Jacob, additional, Hudgins, Lisa Cooper, additional, Ibarretxe, Daiana, additional, Kayikcioglu, Meral, additional, Klingel, Reinhard, additional, Kolovou, Genovefa, additional, Oh, Jun, additional, Planken, R. Nils, additional, Stefanutti, Claudia, additional, Taylan, Christina, additional, Wiegman, Albert, additional, and Schmitt, Claus Peter, additional

Published
2023
Full Text
View/download PDF

42. Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population

Author

Semova, Ivana, Levenson, Amy E., Krawczyk, Joanna, Bullock, Kevin, Williams, Kathryn A., Wadwa, R. Paul, Shah, Amy S., Khoury, Philip R., Kimball, Thomas R., Urbina, Elaine M., de Ferranti, Sarah D., Bishop, Franziska K., Maahs, David M., Dolan, Lawrence M., Clish, Clary B., and Biddinger, Sudha B.

Published
2019
Full Text
View/download PDF

44. Executive Summary

Author

Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Judd, Suzanne E, Kissela, Brett M, Lackland, Daniel T, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Matchar, David B, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Willey, Joshua Z, Woo, Daniel, Yeh, Robert W, and Turner, Melanie B

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology
Published
2015

45. Executive Summary: Heart Disease and Stroke Statistics-2015 Update A Report From the American Heart Association

Author

Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, de Ferranti, Sarah, Despres, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Judd, Suzanne E, Kissela, Brett M, Lackland, Daniel T, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Matchar, David B, McGuire, Darren K, III, Mohler Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Willey, Joshua Z, Woo, Daniel, Yeh, Robert W, Turner, Melanie B, Comm, Amer Heart Assoc Stat, and Subcomm, Stroke Stat

Subjects
Clinical Sciences, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Published
2015

46. Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Author

Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Judd, Suzanne E, Kissela, Brett M, Lackland, Daniel T, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Matchar, David B, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Willey, Joshua Z, Woo, Daniel, Yeh, Robert W, Turner, Melanie B, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Subjects
American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Humans, Heart Diseases, Risk Reduction Behavior, American Heart Association, United States, Stroke, Research Report, AHA Scientific Statements, cardiovascular diseases, epidemiology, risk factors, statistics, stroke, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology
Published
2015

48. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Author

Grundy, Scott M., Stone, Neil J., Bailey, Alison L., Beam, Craig, Birtcher, Kim K., Blumenthal, Roger S., Braun, Lynne T., de Ferranti, Sarah, Faiella-Tommasino, Joseph, Forman, Daniel E., Goldberg, Ronald, Heidenreich, Paul A., Hlatky, Mark A., Jones, Daniel W., Lloyd-Jones, Donald, Lopez-Pajares, Nuria, Ndumele, Chiadi E., Orringer, Carl E., Peralta, Carmen A., Saseen, Joseph J., Smith, Sidney C., Jr., Sperling, Laurence, Virani, Salim S., and Yeboah, Joseph

Published
2019
Full Text
View/download PDF

49. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Author

Grundy, Scott M., Stone, Neil J., Bailey, Alison L., Beam, Craig, Birtcher, Kim K., Blumenthal, Roger S., Braun, Lynne T., de Ferranti, Sarah, Faiella-Tommasino, Joseph, Forman, Daniel E., Goldberg, Ronald, Heidenreich, Paul A., Hlatky, Mark A., Jones, Daniel W., Lloyd-Jones, Donald, Lopez-Pajares, Nuria, Ndumele, Chiadi E., Orringer, Carl E., Peralta, Carmen A., Saseen, Joseph J., Smith, Sidney C., Jr., Sperling, Laurence, Virani, Salim S., and Yeboah, Joseph

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results